Previous 10 | Next 10 |
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments PR Newswire Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023 , which included net proceeds of $242 million ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Biohaven Ltd. (BHVN) is expected to report $-1.33 for Q3 2023
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® PR Newswire - Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscu...
2023-10-06 13:13:50 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven shares slide on pricing $225 million stock offering Biohaven proposes $...
2023-10-03 02:58:39 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven proposes $200M stock offering Biohaven stock jumps 33% in wake of BHV-1...
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commerc...
2023-10-02 16:42:42 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven stock jumps 33% in wake of BHV-1300 drug update Biohaven falls as FDA r...
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
2023-09-27 16:30:10 ET Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline ...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday. Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's se...
Biohaven Ltd’s (NYSE:BHVN) shares are trading lower on Wednesday. The company reported new interim data from the ongoing Phase 1 study of BHV...
Biohaven Ltd. (NYSE:BHVN) stock is moving lower Wednesday. The company recently presented several updates in different fields such as immunology an...